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The Association Between Insulin
Resistance, Depression, and Dementia
Ulrich Vischer, Ildiko Szanto, and Jean-Pierre
Michel
Geriatric Department, Geneva University Hospital, Switzerland.
Drs. Rasgon and Jarvik argue that insulin resistance may
be linked to affective and cognitive disorders (1). Rather
than taking position on this intriguing hypothesis, we wish
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to review the epidemiological data on the association
between insulin resistance and diabetes, depression, and
Alzheimer’s disease (AD).
Insulin Resistance: What Is It?
In a pathophysiological sense, insulin resistance can simply
be defined as any state where the insulin dose–response curve
is shifted to the right. However, in a clinical sense, insulin
resistance is best known in the context of type 2 diabetes and
prediabetes and is usually associated with obesity. Type 2
diabetes is the outcome of a long, slow process where initial
insulin resistance, due to a mix of genetic predisposition and
behavioral factors, worsens to glucose intolerance and
ultimately overt diabetes (i.e., hyperglycemia). Thus, ‘‘insulin
resistance’’ as a clinical concept has no clear boundaries. It is,
however, accompanied by a vast array of abnormalities that
include obesity, hypertension, dyslipidemia, hyperleptine-
mia, and a hypercoagulable state. These symptoms are
nowadays recognized as the ‘‘metabolic syndrome’’ (2),
which implies a high risk for cardiovascular disease even in
the absence of overt hyperglycemia (3).
Two important remarks should be made in connection with
the above considerations: 1) Given the impressive prevalence
of insulin resistance as established by several studies (4,5)
and the lack of recognized diagnostic criteria, a control
group truly free of insulin resistance is difficult to identify
for studies on metabolic, cardiovascular, or psychiatric out-
comes. 2) The interpretation of these types of studies needs to
take into account duration, coexistent metabolic abnormal-
ities, and the presence of diabetes (i.e., the contribution of
insulin resistance per se versus hyperglycemia).
Insulin Resistance and Depression
A link between diabetes and depression has long been
suspected. However, the prevalence of depression in dia-
betes or insulin-resistant state is hard to quantify. In a recent
systematic review, the risk of depression is doubled by dia-
betes, a remarkably consistent figure across studies (6).
A possible explanation would be a common genetic
background accounting for both diabetes and depression.
Alternatively, depression as a ‘‘stress situation’’ could
worsen preexisting insulin resistance and, for example,
convert prediabetes to overt diabetes. The psychological
stress response hypothesis is not only restricted to de-
pression. A major Dutch population study found a correla-
tion between the number of stressful life situations and the
incidence of diabetes (7). One explanation is simply that
these stressful situations would bring the patient more
frequently to the doctor’s attention, and give him more
opportunity to screen for diabetes. However, this relation-
ship was still present when diabetes detected by systematic
screening of the whole population (including newly
discovered cases rather than only self-reported diabetes)
was considered (7).
Whether depression is more frequent with diabetes than
with any other chronic disease is very difficult to demon-
strate convincingly. Actually, the similar rates of depression
in type 1 and type 2 diabetes argue against a major role of
insulin resistance per se (6).
Diabetes and AD
The association between diabetes or insulin resistance and
AD is rather complex and many issues still remain unsolved.
An epidemiological study in search of midlife risk factors
associated with AD has identified the apolipoprotein E-4
(APOE-4) genotype, arterial hypertension, and hypercholes-
terolemia (8). Although the latter two are features of the
metabolic syndrome, diabetes was not identified as a risk
factor in this study. In an older population, the Rotterdam
study found an association between diabetes and dementia
that was stronger for vascular dementia than for AD (9). In the
cross-sectional Kuopio study, impaired glucose tolerance was
found to confer an approximately twofold increase in the risk
for AD; this relationship was strengthened by the exclusion of
APOE e4 carriers (10). Also, in the prospective Honolulu-
Asia Aging Study, a significant increase in the incidence of
dementia in diabetic patients was found over 3 to 4 years, but
the association was once again stronger for vascular dementia
than for AD (11). Importantly, the association between
diabetes and AD was lost when only incident cases of diabetes
or diabetes diagnosed by an elevated postchallenge glucose
level (blood sugar .11 mmol/l during an oral glucose toler-
ance test) were considered. Thus, dementia is more clearly
associated with established diabetes, pointing to a role for
hyperglycemia rather than for insulin resistance per se.
How should we then evaluate the observations that point
towards an association between insulin resistance and AD?
Craft and colleagues (12) have reported reduced insulin
sensitivity in AD patients. This finding was limited to pa-
tients negative for the APOE-4 genotype and to female
patients with mild insulin resistance that did not represent
the full metabolic syndrome (normal fasting blood sugar, no
obesity). In the Kuopio study, impaired glucose tolerance
was associated with a small decline in the Mini-Mental State
Exam and with a low magnitude decrease of long-term
verbal memory (13). These results provide an association
between insulin resistance and cognitive function but fail to
demonstrate a direct causative effect on AD. However, if as
suggested by several studies, mild insulin resistance was
causal in the pathogenesis of cognitive decline and AD, the
remaining question is ‘‘Why is the association between
more severe forms of insulin resistance and AD so difficult
to demonstrate?’’
The importance of insulin signalling in the brain has been
firmly established in several animal studies. One intriguing
finding is the role of the central nervous system in food intake
and obesity. Intracerebroventricular injection of insulin in
monkeys induces reduced food intake and resulted in
significant weight loss (14). Conversely, selective inactiva-
tion of the central nervous system insulin receptor in mice (by
tissue-specific gene knock-out) caused increased food intake,
obesity, and insulin resistance (15). Thus, dysfunction of
brain insulin receptors, possibly induced by the pathological
process underlying AD, can induce peripheral insulin
resistance. Once again, these observations suggest that insulin
resistance in AD is of secondary low magnitude and quite
distinct from the insulin resistance/metabolic syndrome that
underlies type 2 diabetes.
Conclusions and Clinical Implications
The metabolic syndrome and diabetes are associated with
both depression and dementia. However, diabetes is a much
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stronger risk factor for vascular dementia than for AD. The
insulin resistance associated with AD is most likely secondary
rather than causal, of low severity, and distinct from the
metabolic syndrome. Whether therapeutic interventions
targeted at long-term correction of insulin resistance
can improve functional status in AD patients remains to be
demonstrated.
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